^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

EGFR exon 20 insertion mutations in patients with locally advanced or metastatic NSCLC in the German prospective, CRISP Registry real-world cohort (AIO-TRK-0315)

Published date:
03/23/2022
Excerpt:
Most pts (75%) received platin-based combination chemotherapy (ctx) pembrolizumab in 1st-line. Median PFS and OS from start of 1st-line were 8.4 [95%CI, 4.3, na] and 26.2 [95%CI, 10.2, na] months(mo) for the 24 pts with EGFR exon20ins…